OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients.
The monoclonal antibody OKT3 was previously shown to be superior to conventional high-dose steroid therapy for reversal of acute rejection of renal allografts. Furthermore, OKT3 was effective in reversing acute renal or hepatic allograft rejection that was resistant to treatment with steroids, anti-thymocyte globulin, or both. Our analysis demonstrates that OKT3 is also effective in pediatric patients in reversing acute rejection of renal allografts (rescue treatment) or hepatic allografts (primary or rescue treatment).
Goldstein
G
G
Department of Immunobiology, Biotech Division, Ortho Pharmaceutical Corp., Raritan, New Jersey 08869-0602.
Kremer
A B
AB
Barnes
L
L
Hirsch
R L
RL
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005260:Female; D006082:Graft Enhancement, Immunologic; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008212:Lymphocyte Depletion; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal